Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.54 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.54 |
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.54 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30930223 | 1.00 | OPRM1 (0.55) | OPRM1OPRD1MAPK8MAPK9MAPK10 | |
| SCHEMBL22649131 | 0.96 | BDKRB2 (0.57) | OPRM1OPRD1MAPK8MAPK9MAPK10 | |
| SCHEMBL30973973 | 0.91 | MAPK8 (0.43) | OPRM1OPRD1MAPK8MAPK9MAPK10 | |
| SCHEMBL38655084 | 0.88 | BDKRB2 (0.43) | OPRM1OPRD1MAPK8MAPK9MAPK10 | |
| SCHEMBL29824994 | 0.88 | MAPK8 (0.47) | MAPK8MAPK9MAPK10EPHA2BDKRB2 | |
| Bradykinin SCHEMBL7949679 | 0.87 | BDKRB2 (0.67) | OPRM1OPRD1EPHA2BDKRB2NMUR2 | |
| Bradykinin SCHEMBL7949684 | 0.87 | BDKRB2 (0.67) | OPRM1OPRD1EPHA2BDKRB2NMUR2 | |
| SCHEMBL30672572 | 0.87 | BDKRB2 (0.72) | OPRM1OPRD1EPHA2BDKRB2NMUR2 | |
| SCHEMBL30974521 | 0.86 | MAPK8 (0.64) | MAPK8MAPK9MAPK10EPHA2NMUR2 | |
| SCHEMBL30782709 | 0.86 | OPRM1 (0.62) | OPRM1OPRD1EPHA2BDKRB2NMUR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | OPRM1 4101/4885OPRD1 4566/4885MAPK8 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.